Skip to main content
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2017 May 4;13(6):3223–3230. doi: 10.3892/etm.2017.4420

Resveratrol ameliorates diabetic nephropathy in rats through negative regulation of the p38 MAPK/TGF-β1 pathway

Yuan Qiao 1,*, Ke Gao 2,*, Yangwei Wang 1, Xueliang Wang 3, Bo Cui 4,
PMCID: PMC5450784  PMID: 28588674

Abstract

Resveratrol (RSV) has been shown to have a renoprotective effect against diabetic nephropathy, but the underlying mechanisms of this have not been fully elucidated. The aim of the current study was to explore the mechanisms responsible for the therapeutic effects of RSV in rat mesangial cells in vitro and in a rat model of diabetic nephropathy. The viability of CRL-2573 rat mesangial cells and their expression levels of p38, phosphorylated (p)-p38, transforming growth factor beta 1 (TGF-β1) and fibronectin were assessed in response to treatment with high glucose, with or without RSV. Diabetic nephropathy was also induced in Sprague-Dawley rats by streptozotocin treatment. At 8 weeks, basic biochemical parameters and histopathological abnormalities as well as the expression of p38, p-p38, TGF-β1 and fibronectin in rat kidneys were compared between control diabetic rats and those treated with 20 mg/kg RSV daily for 4 weeks. In the mesangial cell line, RSV inhibited high glucose-induced increases in cell viability and fibronectin expression by significantly reducing p38 mitogen-activated protein kinase (MAPK) activation and TGF-β1 expression (P<0.05). In diabetic rats, RSV significantly decreased blood glucose, serum creatinine and urinary albumin levels, as well as the kidney weight and ratio of kidney weight/body weight compared with the control group (P<0.05). Moreover, RSV ameliorated renal histological changes and downregulated the expression of p-p38, TGF-β1 and fibronectin in the kidneys of diabetic rats. These data suggested that RSV protected renal tissue from diabetes-induced injury and that this activity may be via inhibition of the p38 MAPK/TGF-β1 signaling pathway.

Keywords: resveratrol, diabetic nephropathy, p38 mitogen-activated protein kinase/transforming growth factor beta 1 pathway

Introduction

Diabetic nephropathy is a chronic complication of diabetes that is characterized by the expansion of the glomerular mesangium and excessive accumulation of extracellular matrix (ECM) proteins secreted by the proliferating mesangial cells (1,2). The condition decreases patients' quality of life and is an independent risk factor for end-stage renal disease, thereby increasing the risk of mortality (3,4). The efficacy of current treatments for diabetic nephropathy is unsatisfactory in many patients, and diabetic nephropathy has become the leading cause of chronic dialysis (5). Therefore, a consistently effective therapeutic strategy is urgently required for this condition.

An increasing understanding of the molecular mechanisms underlying diabetic nephropathy offers promising support for the development of effective treatment strategies. Previous studies in humans with diabetic nephropathy as well as experimental animal models of the disease have shown that diabetes and high-glucose conditions cause activation of protein kinase C (68) and mitogen-activated protein kinase (MAPK) (911) signaling pathways, which serve key functions in cell proliferation, differentiation and apoptosis. The family of MAPKs includes extracellular signal-regulated kinase-1/2, stress-activated c-Jun N-amino terminal kinase (JNK), p38 MAPK and big MAPK (12,13). Additional studies have demonstrated that mediation of transforming growth factor beta 1 (TGF-β1) by p38 MAPK plays an important role in stimulating cell proliferation and expression of ECM proteins such as fibronectin (14,15).

Resveratrol (RSV) is a natural polyphenolic compound found in various fruits, such as grapes, nuts and berries, as well as in red wine (16). Previous studies have demonstrated that RSV has diverse beneficial health effects including anti-oxidative (17), anti-inflammatory (18), anti-cancer (19), cardioprotective (20) and neuroprotective (21) activities. In relation to diabetic nephropathy, previous reports have indicated that RSV can ameliorate renal insufficiency and pathological changes, as well as prevent high glucose-induced mesangial cell proliferation and glomerular fibronectin expression though multiple signaling pathways under diabetic conditions both in vivo and in vitro. These include the PI3K/Akt, JNK/nuclear factor kappa B (NF-κB) and Akt/NF-κB pathways (18,22,23). However, to the best of our knowledge, it is not known if a direct link exists between p38 MAPK and TGF-β1 in the mechanisms underlying the protective effect of RSV against diabetic nephropathy.

The present study investigated whether RSV treatment could attenuate high glucose-induced mesangial cell viability as well as TGF-β1 expression, p38 activation and fibronectin expression in vitro and diabetes-induced changes in renal function and histological changes in vivo. Furthermore, it was examined whether the protective effect of RSV against diabetic nephropathy was due to the inhibition of TGF-β1 expression and was dependent on p38 MAPK activation.

Materials and methods

Rat mesangial cell line culture and treatment

Cells of the rat mesangial cell line CRL-2573 were purchased from the American Type Culture Collection (Manassas, VA, USA) and routinely cultured at 37°C in Dulbecco's modified Eagle's medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 5.6 µM glucose (normal glucose) or 25 µM glucose (high glucose, HG) and 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA). In cell viability experiment, cells were treated with 10 µM RSV (Cayman Chemical Co., Ann Arbor, MI, USA) or 10 µM of an inhibitor of p38 MAPK called SB-203580 (Cayman Chemical Co.) for 48 h, and the medium and agent were replaced daily. The cells were harvested at 48 h. RSV (10 µM) and SB-203580 (10 µM) were dissolved in dimethyl sulfoxide (DMSO), aliquoted and stored at −80°C until use as treatments. The same volume of DMSO was used as the vehicle control treatment.

Cell viability assay

Cells were seeded in 96-well plates and cultured in DMEM with or without the aforementioned concentrations of HG, RSV and SB-203580 at 37°C for 48 h. Cell viability was evaluated using a 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay (24).

Western blot analysis

Cells were lysed on ice using a radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Haimen, China). Proteins were collected, electrophoresed via 10% SDS-PAGE, then transferred to polyvinylidene fluoride membranes (Roche Diagnostics GmbH, Mannheim, Germany). Then, the membranes were incubated at 4°C overnight with the following primary antibodies: Anti-p38 at a 1:1,000 dilution (ab7952; Abcam, Cambridge, UK), anti-phosphorylated (p)-p38 at a 1:500 dilution (ab4822; Abcam), anti-TGF-β1 at a 1:500 dilution (ab92486; Abcam), anti-fibronectin at a 1:500 dilution (ab2413; Abcam) and β-actin at a 1:1,000 dilution (sc-130656; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The species-specific horseradish peroxidase-conjugated secondary antibodies (ZDR-5306; ZSGB-Bio, Beijing, China) were added at a 1:500 dilution and incubated for 1 h at room temperature to the membranes, and immunoreactive protein bands were detected using a Western Bright Enhanced Chemiluminescence detection system (Advansta, Inc., Menlo Park, CA, USA).

Induction of diabetic rat model and treatment

A total of 50 healthy male Sprague-Dawley rats (8 weeks old, weighing 250±20 g) were obtained from the Animal Experiment Center of Xi'an Jiaotong University (Xi'an, China) and housed under specific pathogen-free conditions. All animals were given ad libitum access to standard food and water and were acclimated for 1 week prior to the beginning of the study. Diabetes was induced using a single dose (55 mg/kg) of streptozotocin (STZ; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) injected intraperitoneally, as described previously (25). The STZ was dissolved in cold sodium citrate buffer (0.1 M, pH 4.5). The normal control (NG) rat group (n=10) received an injection of the same volume of sodium citrate buffer. Blood glucose levels were measured with a portable glucometer (OneTouch UltraVue™; LifeScan China, Shanghai, China) in samples from the tail vein at 72 h after STZ injection, and a plasma glucose level greater than 16.7 mM was considered indicative of diabetes in the rats. The diabetic rats were randomly divided into three groups: Diabetes mellitus (DM) control group (n=10), DM treated with RSV (DM + RSV) group (n=10) and DM treated with vehicle (DM + DMSO) group (n=10). Eight weeks after STZ treatment to induce diabetes, rats in the DM + RSV group were administered orally with 20 mg/kg RSV (dissolved in DMSO and diluted in 0.9% physiological saline) every day for 4 weeks. Over the same period, rats in the DM + DMSO group were treated with the same volume of vehicle (DMSO) as a control. At the end of these experiments, all animals were anesthetized by 10% chloral hydrate (300 mg/kg) and sacrificed by venous air embolism for subsequent analysis. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University School of Medicine.

Histological examination and immunohistochemistry

Rat kidneys were removed, fixed in 10% formalin solution and embedded in paraffin. Sections of 5-µm thickness were cut from the fixed kidney tissue, deparaffinized, hydrated and stained using hematoxylin and eosin. Histological properties were examined using an Olympus BX51 polarizing microscope (Olympus Corporation, Tokyo, Japan). For immunohistochemical staining, 5-µm paraffin-embedded tissue sections were prepared on poly-L-lysine-coated microscope slides. These sections were then deparaffinized, hydrated and incubated in 0.3% H2O2/methanol for 10 min at 25°C to quench endogenous peroxidase activity. The slides were boiled at 100°C for 10 min in 1% citrate buffer (pH 6.0) for antigen retrieval and then blocked with blocking solution containing goat serum (ZSGB-Bio, Beijing China). Sections were incubated with polyclonal antibodies against p38 (1:100; ab7952; Abcam, Cambridge, UK), phosphorylated (p)-p38 (1:200; ab4822; Abcam), TGF-β1 (1:500; ab92486; Abcam), or fibronectin (1:500; ab2413; Abcam) overnight at 4°C. After incubation with a biotinylated secondary antibody (1:20; Bangalore GeNei; Merck KGaA, Darmstadt, Germany; Stored at −20°C) at 25°C for 40 min, horseradish peroxidase was applied to the sections and diaminobenzidine was used as the chromogen. Finally, the sections were counterstained with hematoxylin and examined by light microscopy. Image-Pro Plus 6.0 software (Media Cybernetics, Inc. Rockville, MD, USA) was used for quantitative analysis of the immunohistochemical staining results.

Statistical analysis

Statistical analysis was performed using the Student's t-test and SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). All data are expressed as the mean ± standard deviation of three independent experiments. P<0.05 was considered to indicate a statistically significant difference.

Results

High glucose induced rat mesangial cell viability, TGF-β1 expression and fibronectin expression by promoting p38 MAPK activation

First, the effect of high glucose on the CRL-2573 rat mesangial cell line in vitro. As shown in Fig. 1A, treatment of rat mesangial cells with 25 µM glucose for 24 h led to significantly increased cell viability as compared with a normal glucose treatment of 5.6 µM (P<0.05). In addition, treatment with high glucose significantly increased TGF-β1 and fibronectin expression (P<0.05 for both) and significantly promoted p38 activation, resulting in upregulation of p-p38 (P<0.05). These results suggest that exposure to high glucose caused rat mesangial cells to proliferate, express increased levels of TGF-β1 and fibronectin and exhibit increased levels of p38 activation.

Figure 1.

Figure 1.

Effect of RSV treatment following exposure to high glucose in the mesangial cell line CRL-2573. (A) Relative levels of cell viability among CRL-2573 cells treated with NG, HG, HG + vehicle (DMSO), HG + RSV, or HG + SB. (B) Representative western blot analysis showing p-p38, TGF-β1 and fibronectin expression in CRL-2573 cells treated with NG, HG, HG + vehicle (DMSO), HG + RSV or HG + SB, and the corresponding quantitative data. *P<0.05 vs. NG, #P<0.05 vs. HG. NG, normal glucose; HG, high glucose; RSV, resveratrol; DMSO, dimethyl sulfoxide; SB, SB-203580; p-p38, phosphorylated-p38; TGF-β1, transforming growth factor beta 1; FN, fibronectin.

To further examine the association of rat mesangial cell viability, TGF-β1 expression and fibronectin secretion with p38 activation, cells were simultaneously treated with high glucose and the p38 inhibitor SB-203580 (25 µM) for 24 h. Treatment with SB-203580 significantly inhibited the high glucose-induced viability of rat mesangial cell as well as the high glucose-induced upregulation of TGF-β1 and p-p38, and increased fibronectin accumulation (P<0.05 for all; Fig. 1B). These results suggest that the increases in viability and TGF-β1 and fibronectin expression observed in rat mesangial cells exposed to high glucose are mediated via p38 activation.

RSV inhibited high glucose-induced rat mesangial cell viability, TGF-β1 expression and fibronectin secretion by inhibiting p38 activation

Next, the effects of RSV on rat mesangial cells exposed to high glucose were investigated in vitro. Cells were treated with 25 µM glucose, or 25 µM glucose + 25 µM RSV, or 25 µM glucose + DMSO vehicle for 24 h. Vehicle treatment had no effect on the viability of cells exposed to high glucose, but treatment with RSV resulted in a significant reduction in cell viability compared with high glucose treatment alone (P<0.05; Fig. 1A). Consistently, vehicle treatment had no effect on the upregulation of p-p38, TGF-β1 and fibronectin in cells exposed to high glucose, whereas RSV treatment led to significant decreases in p-p38, TGF-β1 and fibronectin expression compared with high glucose treatment alone (P<0.05 for all; Fig. 1B). These effects of RSV were similar to those of SB-203580 in rat mesangial cells (Fig. 1B). Together these results suggest that RSV inhibited the high glucose-induced viability, upregulated TGF-β1 and increased fibronectin secretion by inhibiting p38 activation.

Effects of RSV on basic biochemical parameters in diabetic rats

After STZ injection, rats that developed diabetes exhibited increases in food intake, water intake and urine output (Table I). At the end of the study, the mean body weight of rats with diabetes in all treatment groups (DM, DM + DMSO and DM + RSV) was significantly lower than that of the NG rats (P<0.05; Table I). In addition, diabetic rats of the DM, DM + DMSO and DM + RSV groups exhibited significantly higher blood glucose concentration, serum creatinine concentration, urinary albumin concentration, kidney weight and ratio of kidney weight/body weight compared with rats in the NG group (P<0.05; Table I). Treatment of diabetic rats with RSV had no effect on body weight, but significantly reduced the aforementioned increases in blood glucose concentration, serum creatinine concentration, urinary albumin concentration, kidney weight and ratio of kidney weight/body weight compared with rats in the DM and DM + DMSO groups (P<0.05; Table I).

Table I.

Effects of resveratrol on basic biochemical parameters in study rats (n=10 per group).

Parameter NG DM DM + DMSO DM + RSV
Food intake (g/d) 108.56±8.23 210.43±11.97a 230.55±17.19a 123.57±9.05ac
Water intake (ml/d) 250.12±15.03 950.66±36.89a 930.51±27.71a 380.49±20.01ac
Urine output (ml/d) 157.21±6.01 965.42±21.58a 872.30±25.34a 350.48±9.18ac
Blood glucose (mM) 4.64±0.68 26.32±7.78a 25.99±8.32a 18.85±5.64ac
Serum creatinine (mM) 30.24±4.56 58.21±8.11a 59.76±9.03a 46.62±7.08ac
Urinary albumin (mg/dl) 4.09±0.52 12.89±0.96a 12.38±0.89a 8.36±0.45ac
Body weight (g) 458.25±11.97 338.06±10.38a 347.77±15.37a 361.05±12.45a
Kidney weight (g) 2.64±0.26 3.31±0.19a 3.48±0.11a 2.92±0.23ac
Kidney weight/body weight (g/kg) 5.89±0.11 10.09±0.13a 10.15±0.09a 7.93±0.18ac

NG, normal control group; DM, diabetes mellitus control group; DM + DMSO, diabetic rats treated with vehicle; DM + RSV, diabetic rats treated with RSV.

a

P<0.05 vs. NG

b

P<0.05 vs. DM.

c

P<0.05 vs. DM + DMSO.

RSV ameliorated diabetes-induced histological changes in the rat kidney

Light microscopy images of kidney sections from NG rats showed the normal structure of the glomerulus and tubules (Fig. 2A). Compared to this, the kidneys of rats with STZ-induced diabetes (DM and DM + DMSO groups) showed histological changes, such as glomerular thickening, interstitial fibrosis, epithelial cellular vacuolar degeneration, hyaline casts and arteriolopathy (Fig. 2B and C). Treatment with RSV attenuated the interstitial and glomerular alterations in the kidneys of diabetic rats (Fig. 2D). The histological changes observed in the kidneys of rats from each experimental group were scored (‘−’ represents the number of changes ≤10%; ‘+’ represents the number of changes >10% and ≤40%; ‘++’ represents the number of changes >40% and ≤70%; ‘+++’ represents the number of changes >70% and ≤100%), and the results are summarized in Table II.

Figure 2.

Figure 2.

Hematoxylin and eosin staining of kidney sections from diabetic rats with and without RSV treatment. (A) Normal glomerulus and tubules of an NG rat. (B) Glomerulus and tubules of a DM rat. Glomerular thickening, interstitial fibrosis and hyaline changes, epithelial cellular vacuolar degeneration, hyaline casts and arteriolopathy are visible. (C) Glomerulus and tubules of a DM rat treated with DMSO vehicle control. Histological alterations of glomeruli and arterioles are similar to those observed in the DM group. (D) Glomerulus and tubules of a DM rat treated with RSV. Milder histological alterations of glomeruli and arterioles are observed. Magnification, ×400. NG, normal control group; DM, diabetes mellitus control group; DM + DMSO, diabetic rats treated with vehicle; DM + RSV, diabetic rats treated with RSV. The dark blue color represents the nuclei and the pink color represents cytoplasm, fibronectin and red blood cells.

Table II.

Results of histopathological examination of kidneys of rats in all experimental groups.

Feature NG DM DM + DMSO DM + RSV
Apical blebbing +++ +++ +
Glomerular thickening +++ +++ +
Interstitial fibrosis +++ +++ +
Arteriolopathy +++ +++ +
Hyaline casts ++ ++

NG, normal control group; DM, diabetes mellitus control group; DM + DMSO, diabetic rats treated with vehicle; DM + RSV, diabetic rats treated with RSV; -, none; +, mild; ++, moderate; +++, severe.

RSV attenuated p38 MAPK activation, TGF-β1 expression and fibronectin accumulation in kidneys of diabetic rats

Immunohistochemical analysis revealed the absence of p38 and p-p38 expression in control kidneys. Quantification of immunohistochemical staining indicated a significant increase in p38 and p-p38 in the distal tubules, collecting ducts, occasional proximal tubules and glomeruli of the kidneys of rats with STZ-induced diabetes compared with normal control rats (P<0.05; Fig. 3, DM and DM + DMSO groups). Staining of kidney sections from rats treated with RSV (DM + RSV group) showed that RSV significantly suppressed the upregulation of p38 and p-p38 compared with the DM group (P<0.05). Quantification of immunohistochemical staining for TGF-β1 showed the same trends, with significantly increased expression in the DM and DM + DMSO groups compared with the control (P<0.05), which was significantly decreased in the DM + RSV group compared with the DM group (P<0.05; Fig. 3).

Figure 3.

Figure 3.

Immunohistochemical staining of kidney sections from diabetic rats with and without RSV treatment. Kidney sections from rats in each experimental group were examined by immunohistochemical staining for p-p38, p38, TGF-β1 and fibronectin (magnification, ×400). Quantitative relative density data are shown on the right. NG, normal control group; DM, diabetes mellitus control group; DM + DMSO, diabetic rats treated with vehicle; DM + RSV, diabetic rats treated with RSV; p-p38, phosphorylated-p38; TGF-β1, transforming growth factor beta 1; FN, fibronectin. *P<0.05 vs. NG, #P<0.05 vs. DM. The blue color represents nuclei and the brown color represents the assessed protein.

In addition, significantly increased accumulation of the ECM protein fibronectin, a known indicator of diabetic nephropathy, was seen in the kidneys of rats with diabetes (DM and DM + DMSO groups) compared with the control group. However, kidney sections from rats in the DM + RSV group showed significantly reduced accumulation of fibronectin compared with the DM group (P<0.05; Fig. 3).

Discussion

RSV has previously been shown to protect against renal insufficiency and pathological changes associated with diabetic nephropathy both in vivo and in vitro (18,22,23). However, the mechanisms responsible for these renoprotective effects remain poorly understood. Increased p38 MAPK activation has been found in the glomeruli of kidneys from animal models of diabetes (26,27) and in mesangial cells cultured under high-glucose conditions (28). These findings suggest that the p38 MAPK pathway may serve a key function in diabetic nephropathy. Moreover, the p38 MAPK pathway is activated by several stress factors that occur in the process of the diabetic nephropathy development, such as hyperglycemia (28,29), hemodynamic abnormalities (30), oxidative stress (31) and proinflammatory cytokines (32). Enhanced expression of p-p38, as a key signaling molecule in the p38 MAPK pathway, is a marker of activation of this signaling pathway (33). Activation of p38 MAPK induces inflammatory cell activation, promotes inflammatory mediator expression and mediates cytokine production, all of which are critical events leading to renal tissue injury in diabetic nephropathy. TGF-β1, as a key cytokine, plays a pivotal role in promoting cell viability and increasing ECM production in diabetic nephropathy (34), and the role of p38 MAPK activation in the progression of diabetic nephropathy in both humans and experimental animals has been linked to its induction of TGF-β1 expression (35). Nevertheless, the effect of RSV treatment on p38 MAPK/TGF-β1 signaling in diabetic nephropathy has remained unclear. In the present study, it was hypothesized that RSV exerts its renoprotective effects in diabetic nephropathy by inhibiting TGF-β1 through suppression of p38 MAPK activation.

To test this hypothesis, the effects of high glucose and RSV on cell viability and expression of p38, p-p38, TGF-β1 and fibronectin were evaluated using the CRL-2573 mesangial cell line. It was found that high glucose significantly increased p38 MAPK activity and TGF-β1 expression in mesangial cells as well as their viability and fibronectin expression. These results are consistent with those of previous studies (23,36,37). For example, Wilmer et al (29) reported that TGF-β1 is critically involved in mesangial cell viability and fibronectin expression. The p38 activity inhibitor SB-203580 was also used to demonstrate that the increases in mesangial cell viability and fibronectin expression induced by exposure to high glucose via upregulation of TGF-β1 were dependent on p38 MAPK activation. Furthermore, RSV treatment significantly inhibited the high glucose-induced increases in p38 MAPK activation, TGF-β1 expression, cell viability and fibronectin expression in mesangial cells. These findings supported the hypothesis that RSV acts through p38 MAPK/TGF-β1 signaling to inhibit high glucose-induced changes in mesangial cells.

The current study also investigated the mechanisms underlying the effects of RSV on renal function and histological abnormalities in rats with STZ-induced diabetes. At 8 weeks after STZ injection, the rats demonstrated typical characteristics of diabetic nephropathy such as hyperglycemia, polyuria and weight loss, and increases in serum creatinine, urinary albumin excretion and the ratio of kidney weight/body weight. Moreover, kidneys from these mice showed pathological changes such as glomerular thickening, interstitial fibrosis and hyaline changes, epithelial cellular vacuolar degeneration, hyaline casts and arteriolopathy. Treatment with RSV significantly reduced these changes in biochemical parameters as well as the pathological alterations observed in diabetic rats. Via immunohistochemical staining, it was observed that RSV treatment also reduced p38 MAPK activation and the expression of downstream molecules including TGF-β1 and fibronectin in the diabetic rat kidney. These findings further indicate that p38 MAPK/TGF-β1 signaling plays a role in the renoprotective effects of RSV in a rodent model of diabetic nephropathy.

In conclusion, both the in vitro findings in high glucose-treated mesangial cells and the in vivo findings in rats with STZ-induced diabetes demonstrated that the renoprotective effects of RSV involve the attenuation of p38 MAPK activation as well as reduced expression of TGF-β1 and fibronectin. Thus, we propose that p38 MAPK/TGF-β1 signaling is inhibited by RSV. The results of the present study provide insight into the mechanisms responsible for diabetic nephropathy, as well as the related effects of RSV. This could be applied in the development of an effective therapeutic strategy for treating this chronic complication of diabetes.

Acknowledgements

This study was supported by the Science and Technology Fund of Shaanxi Province (project no. 2013K12-09-05).

References

  • 1.Miyauchi M, Toyoda M, Kobayashi K, Abe M, Kobayashi T, Kato M, Yamamoto N, Kimura M, Umezono T, Suzuki D. Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med. 2009;48:1615–1620. doi: 10.2169/internalmedicine.48.2137. [DOI] [PubMed] [Google Scholar]
  • 2.Meng XM, Huang XR, Xiao J, Chen HY, Zhong X, Chung AC, Lan HY. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol. 2012;227:175–188. doi: 10.1002/path.3976. [DOI] [PubMed] [Google Scholar]
  • 3.Hill KE, Gleadle JM, Pulvirenti M, McNaughton DA. The social determinants of health for people with type 1 diabetes that progress to end-stage renal disease. Health Expect. 2015;18:2513–2521. doi: 10.1111/hex.12220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Nakagawa T, Lan HY, Glushakova O, Zhu HJ, Kang DH, Schreiner GF, Böttinger EP, Johnson RJ, Sautin YY. Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts. J Am Soc Nephrol. 2005;16:899–904. doi: 10.1681/ASN.2004080689. [DOI] [PubMed] [Google Scholar]
  • 5.Haneda M, Utsunomiya K, Koya D, Babazono T, Moriya T, Makino H, Kimura K, Suzuki Y, Wada T, Ogawa S, et al. A new classification of diabetic nephropathy 2014: A report from joint committee on diabetic nephropathy. Clin Exp Nephrol. 2015;19:1–5. doi: 10.1007/s10157-014-1057-z. [DOI] [PubMed] [Google Scholar]
  • 6.Soetikno V, Watanabe K, Sari FR, Harima M, Thandavarayan RA, Veeraveedu PT, Arozal W, Sukumaran V, Lakshmanan AP, Arumugam S, Suzuki K. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats. Mol Nutr Food Res. 2011;55:1655–1665. doi: 10.1002/mnfr.201100080. [DOI] [PubMed] [Google Scholar]
  • 7.Zhou L, Dong H, Huang Y, Xu L, Zou X, Wang K, Chen G, Lu F. Hu-Lu-Ba-Wan attenuates diabetic nephropathy in type 2 diabetic rats through PKC-α/NADPH oxidase signaling pathway. Evid Based Complement Alternat Med. 2013;2013:504642. doi: 10.1155/2013/504642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Thallas-Bonke V, Jha JC, Gray SP, Barit D, Haller H, Schmidt HH, Coughlan MT, Cooper ME, Forbes JM, Jandeleit-Dahm KA. Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy. Physiol Rep. 2014;2:pii: e12192. doi: 10.14814/phy2.12192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T, Sakai H. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int. 2004;66:1107–1114. doi: 10.1111/j.1523-1755.2004.00798.x. [DOI] [PubMed] [Google Scholar]
  • 10.Lu HJ, Tzeng TF, Liou SS, Da Lin S, Wu MC, Liu IM. Polysaccharides from Liriopes Radix ameliorate streptozotocin-induced type I diabetic nephropathy via regulating NF-κB and p38 MAPK signaling pathways. BMC Complement Altern Med. 2014;14:156. doi: 10.1186/1472-6882-14-156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhang L, Zhang J, Liu X, Liu S, Tian J. Tribbles 3 regulates the fibrosis cytokine TGF-β 1 through ERK1/2-MAPK signaling pathway in diabetic nephropathy. 2014:240396. doi: 10.1155/2014/240396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Barr RK, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs) Int J Biochem Cell Biol. 2001;33:1047–1063. doi: 10.1016/S1357-2725(01)00093-0. [DOI] [PubMed] [Google Scholar]
  • 13.Shin HJ, Choi MS, Ryoo NH, Nam KY, Park GY, Bae JH, Suh SI, Baek WK, Park JW, Jang BC. Manganese-mediated up-regulation of HIF-1alpha protein in Hep2 human laryngeal epithelial cells via activation of the family of MAPKs. Toxicol In Vitro. 2010;24:1208–1214. doi: 10.1016/j.tiv.2010.02.008. [DOI] [PubMed] [Google Scholar]
  • 14.Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: A mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol. 2004;286:F278–F287. doi: 10.1152/ajprenal.00139.2003. [DOI] [PubMed] [Google Scholar]
  • 15.Wei J, Li Z, Chen W, Ma C, Zhan F, Wu W, Peng Y. AEG-1 participates in TGF-beta1-induced EMT through p38 MAPK activation. Cell Biol Int. 2013;37:1016–1021. doi: 10.1002/cbin.10125. [DOI] [PubMed] [Google Scholar]
  • 16.Rajasekaran D, Elavarasan J, Sivalingam M, Ganapathy E, Kumar A, Kalpana K, Sakthisekaran D. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol Med Rep. 2011;4:1211–1217. doi: 10.3892/mmr.2011.555. [DOI] [PubMed] [Google Scholar]
  • 17.Haohao Z, Guijun Q, Juan Z, Wen K, Lulu C. Resveratrol improves high-fat diet induced insulin resistance by rebalancing subsarcolemmal mitochondrial oxidation and antioxidantion. J Physiol Biochem. 2015;71:121–131. doi: 10.1007/s13105-015-0392-1. [DOI] [PubMed] [Google Scholar]
  • 18.Xu F, Wang Y, Cui W, Yuan H, Sun J, Wu M, Guo Q, Kong L, Wu H, Miao L. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell Proliferation: Possible Roles of Akt/NF-κB Pathway. Int J Endocrinol. 2014;2014:289327. doi: 10.1155/2014/289327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta. 2015;1852:1178–1185. doi: 10.1016/j.bbadis.2014.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mokni M, Hamlaoui S, Karkouch I, Amri M, Marzouki L, Limam F, Aouani E. Resveratrol provides cardioprotection after ischemia/reperfusion injury via modulation of antioxidant enzyme activities. Iran J Pharm Res. 2013;12:867–875. [PMC free article] [PubMed] [Google Scholar]
  • 21.Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: Concepts & mechanisms. Curr Med Chem. 2013;20:4640–4645. doi: 10.2174/09298673113209990151. [DOI] [PubMed] [Google Scholar]
  • 22.Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, Chung S, Ko SH, Shin SJ, Choi BS, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. Diabetologia. 2013;56:204–217. doi: 10.1007/s00125-012-2791-y. [DOI] [PubMed] [Google Scholar]
  • 23.Zhang L, Pang S, Deng B, Qian L, Chen J, Zou J, Zheng J, Yang L, Zhang C, Chen X, et al. High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int J Biochem Cell Biol. 2012;44:629–638. doi: 10.1016/j.biocel.2012.01.001. [DOI] [PubMed] [Google Scholar]
  • 24.Cui B, Yang Q, Guan H, Shi B, Hou P, Ji M. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. J Clin Endocrinol Metab. 2014;99:E962–E970. doi: 10.1210/jc.2013-3147. [DOI] [PubMed] [Google Scholar]
  • 25.Schmatz R, Perreira LB, Stefanello N, Mazzanti C, Spanevello R, Gutierres J, Bagatini M, Martins CC, Abdalla FH, da Silva Serres J Daci, et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie. 2012;94:374–383. doi: 10.1016/j.biochi.2011.08.005. [DOI] [PubMed] [Google Scholar]
  • 26.Kang SW, Adler SG, Lapage J, Natarajan R. p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int. 2001;60:543–552. doi: 10.1046/j.1523-1755.2001.060002543.x. [DOI] [PubMed] [Google Scholar]
  • 27.Wang J, Huang H, Liu P, Tang F, Qin J, Huang W, Chen F, Guo F, Liu W, Yang B. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur J Pharmacol. 2006;553:297–303. doi: 10.1016/j.ejphar.2006.08.087. [DOI] [PubMed] [Google Scholar]
  • 28.Tsiani E, Lekas P, Fantus IG, Dlugosz J, Whiteside C. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab. 2002;282:E161–E169. doi: 10.1152/ajpendo.2002.282.1.E161. [DOI] [PubMed] [Google Scholar]
  • 29.Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int. 2001;60:858–871. doi: 10.1046/j.1523-1755.2001.060003858.x. [DOI] [PubMed] [Google Scholar]
  • 30.Ingram AJ, Ly H, Thai K, Kang MJ, Scholey JW. Mesangial cell signaling cascades in response to mechanical strain and glucose. Kidney Int. 1999;56:1721–1728. doi: 10.1046/j.1523-1755.1999.00743.x. [DOI] [PubMed] [Google Scholar]
  • 31.Yamada T, Egashira N, Bando A, Nishime Y, Tonogai Y, Imuta M, Yano T, Oishi R. Activation of p38 MAPK by oxidative stress underlying epirubicin-induced vascular endothelial cell injury. Free Radic Biol Med. 2012;52:1285–1293. doi: 10.1016/j.freeradbiomed.2012.02.003. [DOI] [PubMed] [Google Scholar]
  • 32.Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, Watanabe K. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond) 2011;8:35. doi: 10.1186/1743-7075-8-35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429:403–417. doi: 10.1042/BJ20100323. [DOI] [PubMed] [Google Scholar]
  • 34.Li Y, Chen Q, Liu FY, Peng YM, Wang S, Li J, Li J, Duan SB, Sun L, Ling GH, Luo JH. Norcantharidin inhibits the expression of extracellular matrix and TGF-β1 in HK-2 cells induced by high glucose independent of calcineurin signal pathway. Lab Invest. 2011;91:1706–1716. doi: 10.1038/labinvest.2011.119. [DOI] [PubMed] [Google Scholar]
  • 35.Fujita H, Omori S, Ishikura K, Hida M, Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol. 2004;286:F120–F126. doi: 10.1152/ajprenal.00351.2002. [DOI] [PubMed] [Google Scholar]
  • 36.Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN. Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 1998;54:1107–1116. doi: 10.1046/j.1523-1755.1998.00119.x. [DOI] [PubMed] [Google Scholar]
  • 37.Jeong SI, Kim SJ, Kwon TH, Yu KY, Kim SY. Schizandrin prevents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucose. Food Chem Toxicol. 2012;50:1045–1053. doi: 10.1016/j.fct.2011.11.028. [DOI] [PubMed] [Google Scholar]

Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES